Alexandre Aubourg

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

Geert D’Haens, Séverine Vermeire, Guy Lambrecht et al. · Gastroenterology · 2018 · 295 citations · Full text

Inflammation, Chronic Inflammatory Diseases, Infliximab Dose +8

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

Aurélien Amiot, Jean–Charles Grimaud, Laurent Peyrin‐Biroulet et al. · Clinical Gastroenterology and Hepatology · 2016 · 189 citations

Inflammation, Anti-inflammatory, Immunology +6

Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients

David Ternant, Alexandre Aubourg, Charlotte Magdelaine–Beuzelin et al. · Therapeutic Drug Monitoring · 2008 · 181 citations

Immunology, Gastroenterology, Pharmacotherapy +16

One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study

Aurélien Amiot, Mélanie Serrero, Laurent Peyrin‐Biroulet et al. · Alimentary Pharmacology & Therapeutics · 2017 · 175 citations · Full text

Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the <scp>OBSERV</scp>‐<scp>IBD</scp> cohort

S. Tadbiri, Laurent Peyrin‐Biroulet, Mélanie Serrero et al. · Alimentary Pharmacology & Therapeutics · 2017 · 109 citations · Full text